Bookmark
Forward
Janus Kinase Inhibitors: A Promising Therapeutic Option for Allergic Contact Dermatitis.
Cutis 2023 FebSizes of these terms reflect their relevance to your search.
Janus kinase (JAK) inhibitors represent a promising class of small molecule inhibitors that treat a range of inflammatory skin diseases, such as atopic dermatitis (AD), psoriasis, and alopecia areata. Although the evidence for their use in allergic contact dermatitis (ACD) remains limited, early results from animal studies and case reports are promising. Herein, we provide an overview of JAK inhibitors and the evidence for their use in ACD.
Citation
Hadley Johnson, Jana Guenther, Brandon L Adler, JiaDe Yu. Janus Kinase Inhibitors: A Promising Therapeutic Option for Allergic Contact Dermatitis. Cutis. 2023 Feb;111(2):92-105
Mesh Tags
Substances
PMID: 37075180
View Full Text
